INTRODUCTION: Current medical management of @entity5277 ( @entity5277 ) involves the use of lifelong @entity3147 ( @entity3147 ). @entity5445 ( @entity5445 ), an important intestinotrophic growth factor has been shown to increase intestinal absorption in @entity5277 through augmentation of post-resection intestinal adaptation. This may lead to the reduction of @entity3147 in @entity1 with @entity5277 . AREAS COVERED IN REVIEW: Advancing research of @entity5445 physiology has spurred the growing understanding of the diverse effects of @entity5445 . The development of the degradation resistant @entity5445 analog, teduglutide (Gattex(TM), @entity11989 Pharmaceuticals, Bedminster, NJ), has allowed its exploration as a therapeutic agent in a variety of clinical settings. Recent multicenter, placebo-controlled studies of @entity5445 in @entity5277 @entity1 demonstrate meaningful reductions in @entity3147 requirements with good safety profiles. The reparative and immunomodulatory effects of @entity36040 may also be beneficial in @entity1 with @entity29 ( @entity29 ). Safety concerns about possible carcinogenic properties during long-term use require ongoing evaluation. SUMMARY: @entity5445 appears to offer a novel adjuvant treatment modality for @entity5277 . Promise for its use in other clinical settings like @entity29 has been shown in small pilot studies.

Emerging treatment options for XXXX : potential role of teduglutide.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity36040 :: ('MESH:C494910', 'Chemical') :: ['teduglutide'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD'] @entity3147 :: ('MESH:D044342', 'Disease') :: ['parenteral nutrition', 'PN', 'PN dependence'] @entity5277 :: ('MESH:D012778', 'Disease') :: ['SBS', 'short bowel syndrome'] @entity11989 :: ('MESH:D009261', 'Disease') :: ['NPS'] @entity5445 :: ('2641', 'Gene') :: ['Glucagon-like peptide-2', 'GLP-2']
@entity5277 :: (MESH:D012778,Disease) :: ['short bowel syndrome']
